Liver histological changes after lamivudine treating in chronic hepatitis B patients with HBeAg positive

To investigate the histological changes in liver biopsy tissues taken from chronic hepatitis B patients with HBsAg and HBeAg positive and ALT abnormal after lamivudine therapy for one year. Lamivudine was given orally at the dose of 100 mg once a day for one year. 101 patients were enrolled into thi...

Full description

Saved in:
Bibliographic Details
Published inZhonghua gan zang bing za zhi Vol. 11; no. 9; p. 555
Main Authors Jin, Rong-hua, Lang, Zhen-wei, Yao, Guang-bi, Guo, Xin-hui
Format Journal Article
LanguageChinese
Published China 01.09.2003
Subjects
Adolescent
Adult
Antiviral Agents - therapeutic use
Child
Female
Hepatitis B e Antigens - analysis
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - pathology
Humans
Lamivudine - therapeutic use
Liver - pathology
Liver Cirrhosis - pathology
Male
Online AccessGet more information

Cover

More Information
Summary:To investigate the histological changes in liver biopsy tissues taken from chronic hepatitis B patients with HBsAg and HBeAg positive and ALT abnormal after lamivudine therapy for one year. Lamivudine was given orally at the dose of 100 mg once a day for one year. 101 patients were enrolled into this open-label study. Paired liver biopsies from patients with hepatitis B before and after therapy with lamivudine were studied. Blinded biopsies were evaluated by a histopathologist and scored according to Knodell's histology activity index(HAI). 53.5% (54/101), 51.5% (52/101) and 31.7% (32/101) patients had a reduction of their total hepatic HAI score, necroinflammation and fibrosis scores by >or=2 points or 1 points at the end of one year of lamivudine therapy, compared with their pretreatment values, respectively. There were significant reduction of HAI score, necroinflammation and fibrosis scores from 8.0+/-4.7 to 5.2+/-3.3 (t=7.358, P<0.01), from 5.9+/-3.8 to 3.6+/-2.5 (t=7.298, P<0.01), and from 2.1+/-1.2 to
ISSN:1007-3418